Cargando…

I-2 Can we bypass a muscle metabolic defect?

Detalles Bibliográficos
Autor principal:	Argov, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pacini Editore SpA 2011
Materias:	Lectures by Invited Speakers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235831/

Ejemplares similares

I-13 Muscle ryanodine receptor in congenital myopathies and channelopathies
por: Treves, S., et al.
Publicado: (2011)

I-18 Chronic muscle electrical stimulation in Myotonic Dystrophy
por: Chisari, C.
Publicado: (2011)

I-10 Pathogenesis of muscle degeneration in periodic paralyses and DMD
por: Lehmann-Horn, F., et al.
Publicado: (2011)

I-17 Functional evaluation of muscle impairment in neuromuscular disorders
por: Mazzone, E.
Publicado: (2011)

I-16 Crossing barriers: how medical doctors and researchers can partner with Advocacy Groups
por: Feld, L.
Publicado: (2011)

I-8 Muscle maturation and early pathogenic findings in spinal muscular atrophy: any clues for therapy?
por: Tizzano, E.
Publicado: (2011)

I-3 Treatment of CPT2 deficiency with bezafibrate
por: Laforet, P.
Publicado: (2011)

I-14 Molecular pathomechanism of DM2/PROMM: similarities and differences between DM1 and DM2
por: Meola, G.
Publicado: (2011)

I-12 Timothy Syndrome and Cardiomyopathy
por: Bloise, R.
Publicado: (2011)

I-20 Wearable monitoring systems and rehabilitation
por: De Rossi, D.
Publicado: (2011)

I-11 News in non dystrophic myotonias
por: Deymeer, F.
Publicado: (2011)

I-23 Respiratory rehabilitation in Duchenne Muscular Dystrophy
por: Fiorentino, G., et al.
Publicado: (2011)

I-5 Emerging treatment strategies in mitochondrial disorders
por: Mancuso, M.
Publicado: (2011)

I-1 History of Myology in Italy and its international collections
por: Angelini, C.
Publicado: (2011)

I-15 Neuromyotonia: Potassium channelopathy or non ionic disease?
por: Serratrice, G.
Publicado: (2011)

I-9 Opportunities and challenges of pharmaceutical research and development today
por: Middleton, L.
Publicado: (2011)

I-7 Autoimmune Inflammatory Myopathies: Summary on Pathogenesis and Therapies
por: Dalakas, M.
Publicado: (2011)

I-21 Current therapeutic guidelines in Duchenne Muscular Dystrophy to prolong life
por: Riccio, V., et al.
Publicado: (2011)

I-6 Pharmacological strategies for Muscular Dystrophies. Review of the literature and personal data
por: Politano, L.
Publicado: (2011)

I-19 Neuromuscular electrical stimulation training in facio-scapulo-humeral muscular dystrophy
por: Sacconi, S.
Publicado: (2011)

I-22 Early indicators of respiratory impairment in muscular dystrophies: from bioengineering to rehabilitation
por: D'Angelo, M.G.
Publicado: (2011)

I-4 Long-term follow-up effects on enzyme replacement treatment of adult form of acid maltase deficiency myopathy
por: Angelini, C., et al.
Publicado: (2011)

INSP-06. Recent advances in improving neuropsychological outcomes for paediatric brain tumour patients - Are we entering a new era?
por: Mabbott, Donald
Publicado: (2022)

Headache research - where are we heading?
por: Jensen, Rigmor
Publicado: (2013)

Early exposure hypothesis: where are we now?
por: Lack, Gideon
Publicado: (2011)

Do we need to demonstrate Amyloid in tissue?
por: Magy, Laurent
Publicado: (2015)

Genomics-based breeding in forest trees: are we there yet?
por: Neale, David
Publicado: (2011)

Genome-forward oncology: how do we get there?
por: Ellis, Matthew
Publicado: (2011)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Recruitment to trials - why is it hard and how might we make it less so?
por: Treweek, Shaun
Publicado: (2011)

PReS13-SPK-1582: Activity and damage - we have to measure them
por: Feldman, BM
Publicado: (2013)

PReS13-SPK-1028: Activity and damage - we have to measure them
por: Brunner, H
Publicado: (2013)

INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
por: Jonchere, Barbara, et al.
Publicado: (2022)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

INSP-08. Cerebellar mutism syndrome: incidence, symptoms, risk factors, prognosis. Results and future perspectives from the Nordic-European study of the cerebellar mutism syndrome
por: Sehested, Astrid, et al.
Publicado: (2022)

INSP-03. Neuronal regulation of glioma progression
por: Monje, Michelle
Publicado: (2022)

INSP-17. Augmented Drug Delivery for Pediatric Diffuse Midline Glioma using Convection Enhanced Delivery
por: Souweidane, Mark M
Publicado: (2022)

INSP-14. Novel approaches to molecular diagnostics
por: Sahm, Felix
Publicado: (2022)

INSP-07. Improving cognitive outcomes for children treated for cancer: moving beyond the cure
por: Conklin, Heather
Publicado: (2022)

INSP-01. What to do when you cannot randomize? Leveraging Historical Data in Efficient Study Designs for Pediatric Neuro-Oncology.
por: Onar-Thomas, Arzu
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6cqcn4ddfosk2najd6vq7of50j